MA34805B1 - Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119 - Google Patents
Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119Info
- Publication number
- MA34805B1 MA34805B1 MA35928A MA35928A MA34805B1 MA 34805 B1 MA34805 B1 MA 34805B1 MA 35928 A MA35928 A MA 35928A MA 35928 A MA35928 A MA 35928A MA 34805 B1 MA34805 B1 MA 34805B1
- Authority
- MA
- Morocco
- Prior art keywords
- gpr119
- pyrazole
- modulators
- cyano
- piperidine derivatives
- Prior art date
Links
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title abstract 5
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title abstract 3
- ZCSHWKPISDXCIB-UHFFFAOYSA-N 2-piperidin-4-ylpyrazole-3-carbonitrile Chemical class N#CC1=CC=NN1C1CCNCC1 ZCSHWKPISDXCIB-UHFFFAOYSA-N 0.000 title 1
- 101710163236 Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41644110P | 2010-11-23 | 2010-11-23 | |
| PCT/IB2011/054996 WO2012069948A1 (en) | 2010-11-23 | 2011-11-09 | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34805B1 true MA34805B1 (fr) | 2014-01-02 |
Family
ID=45418722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35928A MA34805B1 (fr) | 2010-11-23 | 2011-11-09 | Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119 |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP2643310A1 (es) |
| JP (1) | JP2013543885A (es) |
| KR (1) | KR20130083915A (es) |
| CN (1) | CN103298801A (es) |
| AP (1) | AP2013006809A0 (es) |
| AR (1) | AR088121A1 (es) |
| AU (1) | AU2011333427A1 (es) |
| BR (1) | BR112013011865A2 (es) |
| CA (1) | CA2814231A1 (es) |
| CL (1) | CL2013001054A1 (es) |
| CO (1) | CO6801716A2 (es) |
| CR (1) | CR20130139A (es) |
| CU (1) | CU20130059A7 (es) |
| DO (1) | DOP2013000102A (es) |
| EA (1) | EA201370118A1 (es) |
| EC (1) | ECSP13012630A (es) |
| GT (1) | GT201300135A (es) |
| MA (1) | MA34805B1 (es) |
| MX (1) | MX2013004083A (es) |
| NI (1) | NI201300044A (es) |
| PE (1) | PE20140409A1 (es) |
| PH (1) | PH12013500677A1 (es) |
| SG (1) | SG189830A1 (es) |
| TW (1) | TWI433843B (es) |
| UY (1) | UY33742A (es) |
| WO (1) | WO2012069948A1 (es) |
| ZA (1) | ZA201302362B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2602813T3 (es) | 2011-06-09 | 2017-02-22 | Rhizen Pharmaceuticals S.A. | Nuevos compuestos como moduladores de GPR-119 |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2017119628A (ja) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | 置換アゾール化合物及び糖尿病治療薬 |
| CN104592120A (zh) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途 |
| CN104892517A (zh) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 酰肼类化合物、其制备方法及用途 |
| CN104610151A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 含酰肼和烷氧苯类结构的化合物、其制备方法及用途 |
| BR112018016794B1 (pt) | 2016-02-18 | 2022-07-19 | Syngenta Participations Ag | Compostos derivados de pirazol ativos em termos pesticidas, composição pesticida, método para controle de pragas, método para a proteção de material de propagação vegetal do ataque por pragas e material de propagação vegetal |
| CN106631992B (zh) * | 2017-01-05 | 2019-01-18 | 桑迪亚医药技术(上海)有限责任公司 | 一种4-氧-3,4-二氢-2h-吡啶-1-甲酸叔丁酯的合成方法 |
| CN115925702B (zh) * | 2022-12-14 | 2025-04-25 | 江西凌富生物科技有限公司 | 一种咪唑并[4,5-c]吡啶衍生物的提纯方法及其咪唑并[4,5-c]吡啶衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009014910A2 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| CA2719507C (en) * | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| NZ596467A (en) * | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
-
2011
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/es not_active Application Discontinuation
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 EA EA201370118A patent/EA201370118A1/ru unknown
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en not_active Ceased
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 PH PH1/2013/500677A patent/PH12013500677A1/en unknown
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/ko not_active Ceased
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/zh active Pending
- 2011-11-09 MA MA35928A patent/MA34805B1/fr unknown
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/xx unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/es unknown
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/ja active Pending
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/pt not_active IP Right Cessation
- 2011-11-21 UY UY0001033742A patent/UY33742A/es unknown
- 2011-11-22 TW TW100142804A patent/TWI433843B/zh not_active IP Right Cessation
- 2011-11-22 AR ARP110104351A patent/AR088121A1/es not_active Application Discontinuation
-
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/es unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/es unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/es unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/es unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/es unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/es unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/es unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013011865A2 (pt) | 2016-08-23 |
| ZA201302362B (en) | 2014-06-25 |
| AU2011333427A1 (en) | 2013-04-11 |
| NI201300044A (es) | 2013-08-01 |
| MX2013004083A (es) | 2013-06-13 |
| CA2814231A1 (en) | 2012-05-31 |
| AP2013006809A0 (en) | 2013-04-30 |
| EP2643310A1 (en) | 2013-10-02 |
| PE20140409A1 (es) | 2014-03-23 |
| CU20130059A7 (es) | 2013-06-28 |
| DOP2013000102A (es) | 2013-07-15 |
| PH12013500677A1 (en) | 2013-05-06 |
| JP2013543885A (ja) | 2013-12-09 |
| CN103298801A (zh) | 2013-09-11 |
| WO2012069948A1 (en) | 2012-05-31 |
| GT201300135A (es) | 2015-02-19 |
| TW201300373A (zh) | 2013-01-01 |
| UY33742A (es) | 2012-06-29 |
| TWI433843B (zh) | 2014-04-11 |
| ECSP13012630A (es) | 2013-07-31 |
| SG189830A1 (en) | 2013-06-28 |
| AR088121A1 (es) | 2014-05-14 |
| CO6801716A2 (es) | 2013-11-29 |
| KR20130083915A (ko) | 2013-07-23 |
| CR20130139A (es) | 2013-06-28 |
| CL2013001054A1 (es) | 2013-09-27 |
| EA201370118A1 (ru) | 2013-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33334B1 (fr) | Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119 | |
| MA34805B1 (fr) | Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119 | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| MA39088B1 (fr) | Compositions et procédés pour moduler des récepteurs farnesoïde x | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| HN2010002774A (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA | |
| MA37525B1 (fr) | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine | |
| ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MA37739A1 (fr) | Composés et compositions destinés à la modulation de l'activité de l'egfr | |
| MA40290A1 (fr) | Agents immunorégulateurs | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
| NO20063191L (no) | Aminobenzazoler som P2Y1-reseptorinhibitorer | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| CR10948A (es) | Compuestos triciclicos, composiciones y procedimientos | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| DE602007002792D1 (de) | Verbindungen und zusammensetzungen als ppar-modulatoren | |
| EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов |